Stada Pharma Services India Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 56.26%
- Profit Growth 49.59%
- Ebitda 27.51%
- Net Worth 24.60%
- Total Assets 25.93%
About Stada Pharma Services India
Stada Pharma Services India Private Limited (SPSIPL) is a leading Private Limited Foreign Company Incorporated In India incorporated in India on 04 July 2013 and has a history of 11 years and seven months. Its registered office is in Thane, Maharashtra.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pradeep Mohakhud, Dirk Welsch, and Tim Adolphs serve as directors at the Company.
Company Details
- Location Thane, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U93000MH2013FTC245193
- Company No.
245193
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
04 Jul 2013
- Date of AGM
22 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Business Outsourcing
Who are the key members and board of directors at Stada Pharma Services India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pradeep Mohakhud  | Director | 12-Aug-2014 | Current |
Dirk Welsch  | Director | 30-Jan-2019 | Current |
| Tim Adolphs | Director | 08-Jun-2022 | Current |
Financial Performance of Stada Pharma Services India.
Stada Pharma Services India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 56.26% increase. The company also saw a substantial improvement in profitability, with a 49.59% increase in profit. The company's net worth Soared by an impressive increase of 24.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stada Pharma Services India?
In 2023, Stada Pharma Services India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stada Pharma Services India?
Stada Pharma Services India has a workforce of 30 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stada Pharma Services India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stada Pharma Services India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
